Replimune Group Inc.

• A study to investigate efficacy of RP2 with nivolumab compared to ipilimumab with nivolumab in adult patients with advanced uveal melanoma n… Pending
  2023-508784-68-00 Phase II/III 5 countries IPILIMUMAB; NIVOLUMAB; RP2
• A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 Recruiting
  2025-521621-33-00 Phase IV 5 countries RP2; RP3; VUSOLIMOGENE ODERPAREPVEC
• A Study to Compare Vusolimogene oderparepvec (VO) Plus Nivolumab With the Doctor's Choice of Treatment in People With Skin Cancer That has G… Recruiting
  2023-508612-29-00 Phase III 6 countries DACARBAZINE CITRATE; NIVOLUMAB; NIVOLUMAB, RELATLIMAB; PACLITAXEL; PEMBROLIZUMAB…
• Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumors Ended
  2024-512710-17-00 Phase I 3 countries
• Study of RP2 alone and in combination with PD1 Blockade in patients with solid tumours Ended
  2024-512866-32-00 Phase I (FiH) 1 country
• Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Ended
  2024-511728-15-00 Phase I (FiH) 3 countries NIVOLUMAB; VUSOLIMOGENE ODERPAREPVEC
• Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS) Ended
  2024-512652-38-00 Phase II 6 countries CEMIPLIMAB; VUSOLIMOGENE ODERPAREPVEC

Showing 1–7 of 7 trials